Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Vaxcyte, Inc. before investing.

In this article, we go over a few key elements for understanding Vaxcyte, Inc.’s stock price such as:

• Vaxcyte, Inc.’s current stock price and volume
• Why Vaxcyte, Inc.’s stock price changed recently
• Upgrades and downgrades for PCVX from analysts
• PCVX’s stock price momentum as measured by its relative strength

About Vaxcyte, Inc. (PCVX)

Before we jump into Vaxcyte, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD). The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV being developed for the prevention of IPD in adults and children. VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; and VAX-GI to prevent dysentery and shigellosis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Want to learn more about Vaxcyte, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Vaxcyte, Inc..

Vaxcyte, Inc.’s Stock Price as of Market Close

As of March 31, 2025, 4:00 PM, CST, Vaxcyte, Inc.’s stock price was $37.760.

Vaxcyte, Inc. is down 45.42% from its previous closing price of $69.180.

During the last market session, Vaxcyte, Inc.’s stock traded between $30.120 and $37.940. Currently, there are approximately 135.20 million shares outstanding for Vaxcyte, Inc..

Vaxcyte, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Vaxcyte, Inc. Stock Price History

Vaxcyte, Inc.’s (PCVX) price is currently down 48.29% so far this month.

During the month of March, Vaxcyte, Inc.’s stock price has reached a high of $76.610 and a low of $30.120.

Over the last year, Vaxcyte, Inc. has hit prices as high as $121.055 and as low as $58.100. Year to date, Vaxcyte, Inc.’s stock is down 53.87%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Vaxcyte, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of March 28, 2025, there were 0 analysts who downgraded Vaxcyte, Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Vaxcyte, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Vaxcyte, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Vaxcyte, Inc. (PCVX) by visiting AAII Stock Evaluator.

Relative Price Strength of Vaxcyte, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of March 28, 2025, Vaxcyte, Inc. has a weighted four-quarter relative price strength of -1.25%, which translates to a Momentum Score of 48 and is considered to be Average.

Want to learn more about how Vaxcyte, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Vaxcyte, Inc. Stock Price: Bottom Line

As of March 31, 2025, Vaxcyte, Inc.’s stock price is $37.760, which is down 45.42% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Vaxcyte, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.